Boardroom Alpha
Meeting calendar
SBRA · Annual meeting · Wednesday, June 17, 2026

Sabra Health Care REIT Inc

7 nominees · 3 ballot items.

Election of seven directors; ratification of PricewaterhouseCoopers LLP as independent auditor for 2026; and advisory approval of the compensation of the Company’s named executive officers (say-on-pay).

Market cap
$5.1B
1Y TSR
+12.3%
Board grade
B-
Record date
Apr 14, 2026
Filing
DEF 14A
Meeting concluded · Jun 17, 2026

Follow how the vote landed and what changed on Sabra Health Care REIT Inc’s board — director track records, governance grades, and ongoing monitoring — on the Boardroom Alpha platform.

Proposals

On the ballot3

  1. 1

    Election of Directors

    ManagementBoard: FOR

    Elect seven nominees to the Board of Directors (Craig A. Barbarosh, Katie Cusack, Michael J. Foster, Lynne S. Katzmann, Ann Kono, Jeffrey A. Malehorn and Richard K. Matros) to serve until the 2027 annual meeting.

  2. 2

    Ratification of Appointment of Independent Registered Public Accounting Firm

    ManagementBoard: FOR

    Ratify the appointment of PricewaterhouseCoopers LLP as Sabra’s independent registered public accounting firm for the fiscal year ending December 31, 2026.

  3. 3

    Advisory Approval of Named Executive Officer Compensation (Say-on-Pay

    ManagementBoard: FOR

    Non-binding, advisory vote to approve the compensation of the Company’s Named Executive Officers as disclosed in the Proxy Statement (the Company’s annual “say-on-pay” vote).

    More detail

    This management proposal asks stockholders to cast a non-binding advisory vote approving the Company’s executive compensation as disclosed in the proxy, including the Compensation Discussion and Analysis, compensation tables and related narrative. Management is seeking shareholder approval as a routine governance practice (annual say-on-pay) to confirm support for its compensation philosophy, which emphasizes long-term value creation through a mix of performance-based TSR awards and time-based restricted stock units, mandatory multi-year deferral and post-vesting holding periods, and robust stock ownership requirements. The Compensation Committee frames the program as aligning executive incentives with stockholder interests by weighting approximately 65% of 2025 equity award value to relative TSR performance and imposing five-year deferral and one-year post-vesting holding periods to encourage long-term decision-making. The proposal is advisory only, but management notes that the Committee will consider the vote outcome when making future pay decisions; historically the say-on-pay received very strong support (approximately 96% in 2025). Key contextual factors include significant recent operational and financial performance (improved Net Debt to Adjusted EBITDA, upgraded credit rating, and positive TSR in 2025), changes to award mix (elimination of FFO-based long-term awards in favor of TSR-only performance awards for 2025) and mandatory deferral features intended to lengthen alignment. Management’s counterparty risk is limited because the vote is non-binding, but the Compensation Committee emphasizes the program’s use of peer-relative TSR, FFO-based annual bonuses, clawback provisions, and double-trigger severance protections to balance incentives and risk. In evaluating the proposal, a sophisticated investor should weigh that the program strongly ties pay to multi-year relative performance and retains governance features (clawbacks, ownership guidelines, majority-independent committee oversight), while also noting potential concerns such as significant equity deferral concentrations, high severance multiples, and substantial discretion in some plan adjustments. The Board recommends approval because it believes the structure appropriately motivates executives to execute the strategic plan and create long-term stockholder value while maintaining retention and succession protections.

Director elections

Nominees on the ballot7

Independent
Tenure on this board
15.7 yrs
Also a director at
Evolent Health Inc (EVH)
Independent
Tenure on this board
5.6 yrs
Also a director at
Cathay General Bancorp (CATY)
Ownership

Top institutional holders10

Latest 13F quarter
1PRINCIPAL FINANCIAL GROUP INC9.7%24,565,647$472M
2VANGUARD PORTFOLIO MANAGEMENT LLC9.2%23,143,248$445M
3BlackRock, Inc.8.9%22,333,918$429M
4STATE STREET CORP4.8%12,099,951$233M
5VANGUARD CAPITAL MANAGEMENT LLC4.5%11,230,748$216M
6BlackRock, Inc.4.2%10,651,577$205M
7JPMORGAN CHASE CO2.8%7,025,253$137M
8GEODE CAPITAL MANAGEMENT, LLC2.5%6,267,391$121M
9CHARLES SCHWAB INVESTMENT MANAGEMENT INC1.9%4,773,303$92M
10LASALLE INVESTMENT MANAGEMENT SECURITIES LLC1.5%3,824,622$74M
Filings

Recent key filings

Periodic reports
Definitive proxies
Reference

Frequently asked questions

When is the Sabra Health Care REIT Inc 2026 annual meeting?
Sabra Health Care REIT Inc (SBRA) holds its 2026 annual shareholder meeting on Wednesday, June 17, 2026.
What is the record date for the Sabra Health Care REIT Inc 2026 meeting?
The record date for the Sabra Health Care REIT Inc 2026 meeting is Tuesday, April 14, 2026. Shareholders of record on or before that date are eligible to vote.
Who are the director nominees for Sabra Health Care REIT Inc's 2026 meeting?
The board is presenting 7 director nominees at the Sabra Health Care REIT Inc 2026 meeting, listed with their independence status and background.
What proposals will shareholders vote on at the Sabra Health Care REIT Inc 2026 meeting?
Shareholders will vote on 3 proposals at the Sabra Health Care REIT Inc 2026 meeting, each tagged with who proposed it and the board's recommendation.
Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer